Endocrine Research
CJC-1295 (No DAC) + Ipamorelin
29 + 5 amino acids · 3367.9 / 711.9 g/mol
WADA: prohibitedView
Sequence, molecular data, research status and testing standards for CJC-1295 (with DAC), written for Canadian researchers.
CJC-1295 with DAC is a synthetic growth hormone-releasing hormone (GHRH) analogue with a chemical linker called a Drug Affinity Complex (DAC). The linker lets the peptide bind albumin in the blood, which extends its half-life from minutes to days.
CJC-1295 with DAC was developed by ConjuChem and studied in early clinical trials, which showed prolonged increases in growth hormone and IGF-1 levels. The company later stopped development. It is discussed in research settings as the long-acting counterpart to CJC-1295 (no DAC).
What it isA lab-made copy of the signal that tells the body's master gland to release growth hormone, built to last longer.
The plain-English storyDeep in your head, a master gland releases growth hormone when it gets a cue. CJC-1295 is a copy of that cue, fitted with a tiny anchor that keeps it in the blood for days instead of minutes, like an actor who refuses to leave the stage. Early studies measured hormone levels, but it never became an approved medicine.
How it works, in simple termsA small add-on lets it stay in the blood for days instead of minutes.
What the science really showsEarly studies measured growth hormone levels. It was never developed into an approved medicine.
Where it stands in CanadaNot an approved medicine in Canada, so nobody can legally sell it to you as one. Also banned in sport.
Educational information only. Not medical advice, and not a claim that this peptide is safe or effective for any use.
Peptide Authority summarizes published research for educational purposes only. Nothing here is medical advice or a claim that CJC-1295 (with DAC) is safe or effective for any use.
| Type | Status in Canada | |
|---|---|---|
| CJC-1295 (no DAC) | GHRH 1-29 analogue, short-acting | Research peptide |
| CJC-1295 (with DAC) | GHRH 1-29 analogue + albumin-binding linker | Research compound |
| Tesamorelin | GHRH 1-44 + protective group | Prescription drug (Egrifta) |
See the CJC-1295 + Ipamorelin profile and the tesamorelin profile.
CJC-1295 with DAC is not authorized by Health Canada as a drug, so it cannot legally be sold for human or animal use in Canada. This is general information, not legal advice. Peptide Authority does not sell CJC-1295 with DAC. Read how peptides are regulated in Canada.
CJC-1295 with DAC is a synthetic growth hormone-releasing hormone (GHRH) analogue with a chemical linker called a Drug Affinity Complex (DAC). The linker lets the peptide bind albumin in the blood, which extends its half-life from minutes to days. It is also known as CJC-1295 DAC, DAC:GRF.
CJC-1295 with DAC is not authorized by Health Canada as a drug, so it cannot legally be sold for human or animal use in Canada. This is general information, not legal advice. Peptide Authority does not sell CJC-1295 with DAC.
Peptide Authority does not sell CJC-1295 with DAC. It is not authorized for human or animal use in Canada, and products sold online cannot be verified without a lot-matched third-party Certificate of Analysis.
Both are GHRH analogues. The version without DAC (Mod GRF 1-29) is short-acting, lasting minutes. The version with DAC has a linker that binds albumin, so it lasts days.
Yes. CJC-1295 (with DAC) is on the World Anti-Doping Agency (WADA) Prohibited List: Prohibited: S2 (GHRH and its analogues).
29 + 5 amino acids · 3367.9 / 711.9 g/mol
This profile is for information only and is not medical advice. Products sold by Peptide Authority are for in-vitro laboratory research only and are not for human or animal consumption. See our full disclaimer.